Triple-negative breast cancers (TNBCs) represent approximately 10–15% of all breast cancers and are a highly aggressive subtype of tumors that lack estrogen receptor (ER), progesterone receptor (PR) and HER2 gene amplification1,2. The gene discussed is ESR1; the disease is triple-negative breast carcinoma.